Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 19;7:13556. doi: 10.1038/s41598-017-13786-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The level of human tau increases over time in the brain of mice injected with AAV-P301S. (a) Detection of overexpressed tau using the human tau-specific HT7 antibody in mouse forebrain homogenates at 1.5, 3 and 7 months post-AAV injection. Actin is used as loading control. *Indicates higher molecular weight human tau species observed in the P301S group of mice. (b) Relative human tau levels measured by western blotting of mouse forebrain homogenates (1.5, 3 and 7 months post- injection). Blots are shown in Supplementary Figure 1. For each animal, human tau values are normalized to actin and plotted as percentage of the mean value for the AAV-WT group at 1.5 months. Statistical analysis: two-way ANOVA followed by Tukey’s post-hoc test, group × time effect F(2,30) = 4.89, **p < 0.01; ***p < 0.001. (c) The graph compares the level of human tau (HT7/TAU-13 AlphaLisa) in total soluble proteins from forebrain homogenates, as well as in the soluble and insoluble fractions following sarkosyl extraction. Samples are derived from AAV-WT and AAV-2P mice, 7 months after AAV injection; n = 8 mice per group.